Advisement provided on Oxford Biomedica's share offering by our legal office
Oxford Biomedica Raises £60 Million to Expand Global CDMO Network
Oxford Biomedica plc (OXB), a global leader in cell and gene therapy, has successfully raised £60 million through an equity placing. The company, listed on the London Stock Exchange, plans to use these funds strategically to expand its contract development and manufacturing organisation (CDMO) network, with a primary focus on the United States.
The equity placing represented 13.1 percent of OXB's issued share capital and involved new and existing institutional investors. The transaction was advised by global law firm White & Case LLP, with partner Jonathan Parry leading the team from London. The team also included partner Laura Sizemore (London), counsel Bob Lehner (Chicago), and associate George Davie (London).
The funds will be used to make several strategic investments. Firstly, Oxford Biomedica aims to establish new commercial-scale Good Manufacturing Practice (GMP) capacity in the U.S., incorporating advanced automation and fill-finish services. This expansion is designed to increase global throughput and strengthen capacity for late-stage and commercial supply.
Secondly, the company will enhance process quality and yields to meet growing client demand across all clinical phases, including late-stage and commercial supply. Thirdly, Oxford Biomedica will invest in digitization and data-driven systems to improve efficiency and visibility across clinical and commercial projects. This will complement the physical expansions by enhancing operational capabilities.
These investments are part of a broader strategy to expand Oxford Biomedica's global CDMO network, ensuring it remains competitive in the growing viral vector market by providing comprehensive services across the U.K., U.S., and continental Europe.
White & Case has service areas in Capital Markets, Financial Institutions, Life Sciences and Healthcare, Western Europe, North America, United States, and United Kingdom. Bob Lehner specializes in Capital Markets and Technology, while Laura Sizemore specializes in Capital Markets, Life Sciences and Healthcare, Mining & Metals, and Financial Institutions. George Davie specializes in Capital Markets, Financial Institutions, Technology, and Energy Transition.
The transaction involved Jefferies as global coordinator and joint bookrunner, and RBC Capital Markets as joint bookrunner. Global law firm White & Case LLP advised Jefferies and RBC Capital Markets on this equity placing. Jonathan Parry, who led the White & Case team, specializes in Capital Markets, Financial Institutions, Energy, and Energy Transition.
For queries, the local media contact can be reached.
[1] Oxford Biomedica press release, 2022. [2] White & Case press release, 2022. [3] Jefferies press release, 2022.
- Oxford Biomedica's £60 million capital raised will be utilized to broaden their contract development and manufacturing organization (CDMO) network, with a major emphasis on enhancing US presence.
- The strategic investments include establishing commercial-scale Good Manufacturing Practice (GMP) capacity in the United States, incorporating advanced technology for fill-finish services.
- The aim is to increase global throughput and strengthen capacity for late-stage and commercial supply.
- To meet growing client demand, Oxford Biomedica plans to enhance process quality and yields across all clinical phases.
- In addition, Oxford Biomedica will invest in digitization and data-driven systems, improving efficiency and visibility across clinical and commercial projects.
- White & Case LLP, a global law firm, served as advisor for the equity placing, with Jonathan Parry, a partner specializing in Capital Markets, Financial Institutions, Energy, and Energy Transition, leading the team.
